Pantoprazolo Aurobindo (Pantoprazole)

Pantoprazolo Aurobindo is a proton‑pump inhibitor that addresses disorders related to excess gastric acid.

• Gastro‑esophageal reflux disease (GERD): alleviates heartburn and esophageal irritation.
• Erosive esophagitis: promotes healing of acid‑induced esophageal lesions.
• Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with gastrin‑producing tumors.
• Prevention of gastric ulcer recurrence: reduces risk of ulcer redeveloping after healing.

• Pantoprazole inhibits the H+/K+ ATPase enzyme (gastric proton pump) located in the parietal cells of the stomach lining. By blocking this final step of acid secretion, it markedly lowers gastric acidity, allowing damaged mucosa to heal and decreasing the stimulus for acid‑related symptoms.

Pantoprazolo Aurobindo may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache
• Diarrhea
• Nausea
• Abdominal pain
• Flatulence
• Constipation

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis)
• Clostridioides difficile‑associated colitis
• Low magnesium levels (hypomagnesemia)
• Acute interstitial nephritis
• Fracture risk with long‑term use
• Liver enzyme elevations

When prescribing Pantoprazolo Aurobindo, clinicians should consider several safety aspects.

• Renal impairment: adjust use based on renal function.
• Hepatic impairment: use with caution in severe liver disease.
• Long‑term therapy: monitor bone health and magnesium levels.
• Drug interactions: review concomitant medications for potential interactions.
• Pregnancy and lactation: evaluate risk‑benefit before use.
• Store below 25°C: keep in the original packaging, protect from moisture and light.

Pantoprazolo Aurobindo can interact with several medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

• Ketoconazole and itraconazole: reduced antifungal absorption.
• Atazanavir: decreased antiviral effectiveness.
• Clopidogrel: diminished antiplatelet activity.

Moderate Interactions (Monitor Closely)

• Warfarin: potential alteration of INR values.
• Digoxin: possible increase in serum levels.
• Methotrexate: reduced renal clearance may raise toxicity risk.